Impact of adjuvant therapy toxicity on quality of life and emotional symptoms in patients with colon cancer: a latent class analysis
- 16 July 2020
- journal article
- research article
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 23 (3) , 657-662
Abstract
Objective To identify distinct trajectories of toxicity in colorectal cancer (CRC) patients after adjuvant chemotherapy and its impact on quality of life (QoL) and psychological symptoms. Methods A prospective, multicenter study was conducted in 157 patients. A latent class analysis defined the unobserved latent constructs that can be predicted as symptom clusters, considering the intensity of four types of adverse events (AEs). Patients completed EORTC-QLQ-C30, BSI-18, PDRQ-9, and DRS scales. Results Ninety-six percent had some degree of toxicity, with grades 3–4 being the most common: neurotoxicity (7.2%), hematological (13.1%), digestive (5.2%), and skin toxicity (1.4%). Three distinct latent classes were identified (high [72.5%], mild [16.9%], and low [10.6%] toxicity). Patients with high toxicity had the worst QoL scores and moderately high somatization and psychological distress scores. Conclusions Adjuvant chemotherapy for CRC was associated with frequent toxicity that negatively impacted QoL and psychological wellbeing.Keywords
Funding Information
- Sociedad Española de Oncología Médica (FSEOM-Onvida for Projects on Long Survivors and Quality of Life. SEOM (Spanish Society of Medical Oncology) 2015)
This publication has 14 references indexed in Scilit:
- Impact of Patient Factors on Recurrence Risk and Time Dependency of Oxaliplatin Benefit in Patients With Colon Cancer: Analysis From Modern-Era Adjuvant Studies in the Adjuvant Colon Cancer End Points (ACCENT) DatabaseJournal of Clinical Oncology, 2016
- Oxaliplatin As Adjuvant Therapy for Colon Cancer: Updated Results of NSABP C-07 Trial, Including Survival and Subset AnalysesJournal of Clinical Oncology, 2011
- Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Folinic Acid As Adjuvant Therapy for Stage III Colon CancerJournal of Clinical Oncology, 2011
- Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC TrialJournal of Clinical Oncology, 2009
- Individualized Prediction of Colon Cancer Recurrence Using a NomogramJournal of Clinical Oncology, 2008
- Pooled Analysis of Fluorouracil-Based Adjuvant Therapy for Stage II and III Colon Cancer: Who Benefits and by How Much?Journal of Clinical Oncology, 2004
- A patient-doctor relationship questionnaire (PDRQ-9) in primary care: development and psychometric evaluationGeneral Hospital Psychiatry, 2004
- Validation of a Decision Regret ScaleMedical Decision Making, 2003
- Applied Latent Class AnalysisCanadian Journal of Sociology, 2003
- The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in OncologyJNCI: Journal of the National Cancer Institute, 1993